Cormedix Inc. (CRMD)
AI stock analysis · as of Aug 14, 2026
Loading microstructure…
CorMedix is a small-cap specialty pharma that has rapidly transitioned from clinical-stage to commercial, driven by DefenCath, the only FDA-approved antimicrobial catheter lock solution. FY2025 revenue exploded to $311.7M (+617% YoY) with 52% net margins and $173M FCF, boosted by the August 2025 Melinta acquisition adding hospital infrastructure and the REZZAYO/VABOMERE portfolio. The core investment question: can CRMD sustain and grow DefenCath economics through the July 2026 TDAPA reimbursement cliff, execute Melinta integration, and deliver on REZZAYO's prophylaxis Phase 3 readout in Q2 2026 — enough to justify durable earnings before pricing normalizes in 2027?
valuationOptically cheap on trailing metrics (EV/EBITDA 2.3x, P/E 3.75x, FCF yield 19%, P/S 1.6x) but forward P/E of 23x tells the truer story — the market is pricing in the 2026 reimbursement cliff, making this a fair-to-modestly-cheap setup contingent on 2027 pricing recovery and REZZAYO success.
This analysis is from Aug 14, 2026. Want the latest on CRMD, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Explosive commercial ramp: revenue grew from $0 (2023) to $43M (2024) to $312M (2025); FY25 net income of $163M and FCF of $173M against a $639M market cap implies a ~19% FCF yield and EV/EBITDA of just 2.3x
- · DefenCath has covered ~60% of U.S. outpatient dialysis centers by addressable patients, with real-world evidence showing 70% reduction in CRBSI-related hospitalizations — strong payer/provider value proposition
- · Multiple shots on goal: REZZAYO prophylaxis Phase 3 top-line data in Q2 2026 targets a >$2B market vs. current $250-350M treatment-only; DefenCath TPN indication targets $500-750M TAM
- · Post-TDAPA add-on payment from January 2027 estimated 3-5x higher than H2 2026 trough level, implying the reimbursement cliff is temporary rather than terminal
- · BARDA non-dilutive funding up to $144.6M through 2034 supports pipeline development with limited shareholder cost; balance sheet has $145M cash roughly matching $149M debt
- · News flow is constructive: Q2 2026 earnings beat drove biggest single-day gain in ~10 months, sentiment score 0.72, and 21% short float with 17-day cover ratio creates squeeze potential on positive catalysts
Bear case
- · DefenCath TDAPA reimbursement expires July 1, 2026, causing a material net price decline in H2 2026 before an uncertain 2027 recovery — CMS methodology is not guaranteed to be favorable
- · NTAP for inpatient DefenCath expires November 14, 2026, eliminating up to 75% WAC reimbursement add-on for hospital stays — pressuring the Melinta cross-sell thesis
- · Trailing P/E of 3.75x looks optically cheap but forward P/E of 23x reflects the reimbursement reset; current earnings are not the run-rate
- · Extreme single-source manufacturing concentration: one FDA-approved CMO for each DefenCath API and finished dose — any cGMP disruption would be catastrophic to the revenue base
- · Debt-to-equity of 33.7x is extremely elevated (post-Melinta acquisition financing), leaving limited flexibility if reimbursement or trial catalysts disappoint
- · REZZAYO NDA/IP remains with Mundipharma until June 2028 or prophylaxis approval; a Phase 3 failure in Q2 2026 would eliminate the single largest growth catalyst and milestone economics
- · MINOCIN IV generic litigation (Nexus Federal Circuit appeal, Gland Pharma ANDA) threatens Melinta portfolio value
Catalysts
- · REZZAYO ReSPECT Phase 3 prophylaxis top-line data in Q2 2026 — largest single binary event, addressing >$2B TAM
- · Q3 2026 supplemental filing for Rezzayo fungal indication per CEO guidance
- · Next earnings August 13, 2026 — updated DefenCath run-rate and pre-cliff guidance
- · CMS post-TDAPA add-on payment methodology decision — critical for 2027 pricing recovery visibility
- · Elevated short interest (21% of float, 17-day cover) creates squeeze potential on any positive catalyst surprise
- · Melinta cost synergy realization and hospital cross-sell execution through 2026
Key risks
- · Adverse CMS reimbursement methodology decision post-TDAPA — could permanently impair DefenCath economics
- · REZZAYO Phase 3 prophylaxis trial failure in Q2 2026
- · Single-source CMO supply disruption for DefenCath
- · Melinta integration missteps and MINOCIN generic entry pressuring acquired revenue
- · Concentration risk: DefenCath revenue tied to CMS ESRD bundle policy — a single regulatory decision could reset the model
What to watch
- · Q2 2026 REZZAYO ReSPECT Phase 3 top-line data — binary catalyst
- · August 13, 2026 earnings — DefenCath run-rate and 2026 guidance updates
- · CMS post-TDAPA add-on payment methodology announcements ahead of July 1, 2026 cliff
- · Q3 2026 REZZAYO supplemental filing per CEO guidance
- · Short interest dynamics — 21% float short, 17-day cover ratio; watch for squeeze on positive prints
- · 52-week low of $6.13 as key technical support; $14.96 high as resistance
Key metrics
Price target rationale
Base $12: ~10x forward earnings normalized for H2 2026 reimbursement reset, in line with specialty pharma peers pre-catalyst. Bull $18: REZZAYO Phase 3 success + favorable CMS post-TDAPA methodology, ~15x forward earnings on expanded TAM. Bear $5.50: REZZAYO failure and/or unfavorable CMS ruling drives forward P/E compression toward book value (~$5.60 implied by P/B 1.46x).
On Wall Street's view (mixed): The $15 consensus target implies ~84% upside, which is directionally reasonable given the FCF and pipeline optionality, but it appears to underweight the 2026 reimbursement trough that could compress H2 2026 earnings materially. A base case in the $11-13 range better reflects the cliff, with meaningful upside only on REZZAYO success or favorable CMS ruling.
Latest filing (10-K)
CorMedix is a newly scaled specialty pharma company built around DefenCath, the only FDA-approved antimicrobial catheter lock solution, facing a known 2026 reimbursement trough before a potential 2027 pricing recovery, while betting its next leg of growth on REZZAYO's prophylaxis approval in a market estimated at over $2 billion.
CorMedix is a specialty biopharmaceutical company commercializing hospital and clinic-focused infectious disease products. Its flagship product, DefenCath (taurolidine/heparin catheter lock solution), is the only FDA-approved antimicrobial catheter lock solution in the U.S., launched in 2024 for hemodialysis patients. In August 2025, CorMedix acquired Melinta Therapeutics, adding six marketed anti-infective and one cardiovascular product, transforming it into a multi-product commercial-stage company generating revenue from hospital formulary sales and government reimbursement programs.
What the news says · bullish
The dominant storyline is a strong Q2 2026 earnings beat driven by robust DefenCath sales, which triggered CRMD's best single-day gain in nearly 10 months. The CEO's guidance for a supplemental filing for a fungal disease treatment (Rezzayo) by Q3 adds a meaningful near-term catalyst beyond the core catheter-lock therapy business. This follows a pattern of positive momentum — Q1 also saw a triple-digit revenue surge and raised full-year guidance — suggesting the commercial ramp is gaining traction. A governance settlement win and institutional buying (Hennion & Walsh) provide additional constructive signals. The main risk flags are a March 2026 double-digit single-day drop (context unclear from headlines) and analyst price target divergence, indicating some uncertainty remains around valuation and execution.
This analysis is from Aug 14, 2026. Markets move. Get the current read on CRMD and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.